Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences
September 06 2017 - 7:30AM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage
specialty pharmaceutical company dedicated to developing and
commercializing innovative transdermal pharmaceutically-produced
cannabinoid treatments, today announced that Armando Anido,
Chairman and Chief Executive Officer, will present a company
overview at the upcoming Rodman & Renshaw 19th Annual Global
Investment Conference at the Lotte New York Palace, New York on
Tuesday, September 12, 2017 at 9:10 a.m. ET.
The Company will also be participating in
investor meetings at the 15th Annual Morgan Stanley Global
Healthcare conference at the Grand Hyatt Hotel, New York on
Wednesday September 13, 2017.
To listen to a webcast of the Rodman &
Renshaw presentation live, please visit the Investor Relations page
of www.zynerba.com. A replay of the webcast will be available for
90 days following the conclusion of the event.
About Zynerba Pharmaceuticals,
Inc. Zynerba Pharmaceuticals (NASDAQ:ZYNE) is dedicated to
improving the lives of people with severe health conditions where
there is a high unmet medical need by developing and
commercializing pharmaceutically-produced transdermal cannabinoid
medicines designed to meet the rigorous efficacy and safety
standards established by global regulatory agencies. Through the
discovery and development of these potentially life-changing
medicines, Zynerba seeks to improve the lives of patients battling
severe, chronic health conditions including epilepsy, Fragile X
syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic
pain. Learn more at www.zynerba.com and follow the Company on
Twitter at @ZynerbaPharma.
Cautionary Statement on Forward Looking
StatementsAny statements in this press release about
future expectations, plans and prospects for the Company, including
the Company’s expectations regarding the completion, timing and
size of the option exercise, the Company’s anticipated proceeds
therefrom and other statements containing the words “anticipate,”
“believe,” “estimate,” “upcoming,” “plan,” “target”, “intend,”
“expect” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on
management’s expectations and assumptions as of the date of this
press release and are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
expressed or implied by such statements. These risks and
uncertainties include, without limitation, risks and uncertainties
associated with market conditions and the satisfaction of customary
closing conditions related to the proposed offering, as well as
other risks and uncertainties discussed in the Risk Factors set
forth in the Company’s Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q filed with the SEC and in other filings the
Company makes with the SEC from time to time. In addition, the
forward-looking statements included in this press release represent
the Company’s views only as of the date of this press release.
Important factors could cause our actual results to differ
materially from those indicated or implied by forward-looking
statements, and as such we anticipate that subsequent events and
developments will cause our views to change. However, while we may
elect to update these forward-looking statements at some point in
the future, we specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Investor Contact
Will Roberts, VP Investor Relations and Corporate Communications
484.581.7489
robertsw@zynerba.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024